Clinical Study of 68GA-labeled Claudin 18.2 Developer Combined with PET/CT for Imaging of Gastric or Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer
Latest Information Update: 24 Oct 2024
At a glance
- Drugs SNA 014 (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Pancreatic cancer
- Focus Adverse reactions; Diagnostic use
- Sponsors SmartNuclide Biopharma
- 24 Oct 2024 New trial record